abbrevi
dic
dissemin
intravascular
coagul
dmpge
dimethyl
prostaglandin
elam
endothelialleukocyt
adhes
molecul
fh
fulmin
hepat
hbv
hepat
b
viru
hbcag
hepat
b
core
antigen
hbsag
hepat
b
surfac
antigen
hepat
encephalopathi
ifn
interferon
mhc
major
histocompat
complex
mhv
murin
hepat
viru
pca
procoagul
activ
pg
prostaglandin
tnf
tumor
necrosi
factor
oligoadenyl
synthetas
fulmin
hepat
fh
consequ
hepat
b
viru
infect
rapidli
fatal
diseas
occur
within
week
onset
jaundic
lead
acut
liver
insuffici
complic
hepat
encephalopathi
occur
less
week
onset
jaundic
diseas
term
acut
fh
wherea
subacut
fh
defin
acut
liver
failur
complic
week
month
onset
jaundic
incid
fh
thought
case
acut
hepat
mortal
vari
sever
stage
ii
stage
iv
encephalopathi
death
attribut
number
complic
fh
case
caus
death
unknown
autopsi
liver
show
massiv
hepat
necrosi
collaps
minim
evid
hepat
regener
time
present
viral
antigen
hbv
surfac
core
antigen
hbsag
hbcag
viral
genom
hbvdna
usual
found
liver
tissu
satisfactori
medic
treatment
exist
fh
manag
date
consist
support
measur
includ
replet
plasma
coagul
factor
glucos
infus
treatment
sepsi
correct
fluid
electrolyt
imbal
signific
benefit
corticosteroid
shown
set
recent
random
control
trial
charcoal
hemoperfus
also
shown
benefit
liver
transplant
propos
patient
fh
howev
surviv
ill
patient
stage
iii
iv
hepat
encephalopathi
remain
suggest
transplant
offer
consid
earlier
pathogenesi
diseas
unknown
appear
involv
viral
factor
well
host
factor
includ
age
sex
immun
statu
host
directli
cytopath
hepatocyt
rather
hepat
injuri
may
result
humor
cellular
immunemedi
process
evid
exist
experiment
model
fh
man
suggest
follow
viral
infect
immun
coagul
system
activ
result
intravascular
thrombosi
local
microcirculatori
disturb
within
liver
agent
interfer
activ
classic
immun
coagul
system
shown
benefici
set
fh
base
upon
observ
develop
follow
hypothesi
pathogenesi
fh
fig
viral
infect
result
cellular
andor
humor
immun
respons
either
directli
injuri
liver
result
activ
immun
coagul
system
format
sinusoid
microthrombi
platelet
activ
hepat
necrosi
failur
regul
pathway
result
clinic
syndrom
fh
remaind
chapter
discuss
evid
form
basi
hypothesi
humor
immun
respons
hbv
vigor
immun
respons
hbsag
report
fh
b
infect
hbsag
clear
serum
significantli
faster
patient
fh
serum
patient
nonfh
furthermor
signific
proport
patient
fh
antibodi
respons
hbsag
antihbsag
detect
present
sinc
littl
antibodi
hbsag
detect
acut
viral
hepat
b
infect
postul
presenc
antigen
antibodi
immun
complex
patient
fh
may
respons
sever
liver
diseas
ensu
recent
demonstr
antibodi
translat
product
pre
region
envelop
gene
hbv
occur
earli
cours
fh
b
may
particip
sever
hepat
injuri
earli
clearanc
viru
characterist
diseas
result
suggest
enhanc
humor
immun
respons
product
antibodi
may
lead
arthuslik
reaction
sinusoid
liver
ensu
ischem
necrosi
suggest
cellular
immun
mechan
respons
hepatocellular
injuri
viral
hepat
elimin
viral
infect
hepatocyt
depend
upon
recognit
viral
determin
associ
major
histocompat
complex
mhc
protein
class
infect
hepatocyt
cytotox
cell
recent
studi
suggest
natur
killer
nk
cell
play
role
acut
phase
diseas
autolog
cytotox
studi
suggest
target
antigen
known
express
surfac
infect
hepatocyt
hbcag
andor
hbsag
use
dualcolor
fluoresc
analysi
elev
cytotox
cell
well
reduct
suppressor
cell
found
peripher
blood
patient
fh
serial
studi
show
imbal
two
subset
cell
acut
phase
infect
recoveri
phase
tabl
attempt
identifi
intrahepat
lymphocyt
subpopul
patient
fh
demonstr
increas
cytotox
cell
liver
tissu
cell
broad
contact
surfac
hepatocyt
contrast
helper
cell
scarc
liver
tissu
result
suggest
loss
suppressor
cell
increas
number
cytotox
cell
liver
patient
acut
fh
case
fh
associ
moder
sever
consumpt
coagulopathi
dissemin
intravascular
coagul
dic
histopatholog
studi
man
reveal
sever
extens
hepat
cell
necrosi
conspicu
common
abnorm
seen
liver
morpholog
resembl
hepat
necrosi
produc
experiment
rabbit
schwartzman
reaction
use
escherichia
coli
endotoxin
led
hypothesi
acut
sever
extens
hepat
cell
necrosi
seen
case
probabl
result
anox
state
caus
instanc
intrahepat
circulatori
disturb
thrombi
format
note
around
necrot
area
signific
number
case
fh
man
experiment
evid
support
role
activ
immun
coagul
system
seen
murin
model
viral
hepat
product
macrophag
serin
proteas
procoagul
activ
pca
preced
genet
link
evolut
fh
abrog
product
pca
either
heparin
andor
prostaglandin
prevent
fh
although
prolong
surviv
macrophag
stimul
endotoxin
induc
express
monokin
tumor
necrosi
factor
tnf
shown
capabl
initi
induct
procoagul
endotheli
cell
activ
endotheli
cell
also
produc
adhes
molecul
endothelialleukocyt
adhes
molecul
promot
adhes
lymphocyt
endotheli
ceil
produc
vascular
stasi
normal
function
endothelium
inhibit
thrombosi
therefor
nonstimul
endotheli
cell
littl
surfac
procoagul
activ
normal
augment
anticoagul
function
activ
protein
c
howev
follow
stimul
endotheli
cell
balanc
tip
favor
thrombosi
promot
coagul
result
interact
monocyt
endotheli
cell
may
benefici
limit
spread
infecti
agent
act
natur
defenc
mechan
hand
tendenc
coagul
may
lead
dissemin
intravascular
coagul
seen
certain
infect
malign
may
detriment
host
ifn
normal
found
measur
quantiti
serum
detect
acut
phase
number
viral
infect
pg
shown
benefici
effect
varieti
anim
model
hepat
failur
due
toxin
acetaminophen
galactosamin
alcohol
hypoxia
ischemia
immun
mediat
tabl
group
shown
hepat
cytoprotect
dimethyl
fulmin
murin
viral
hepat
infect
furthermor
preliminari
evid
suggest
pg
prevent
evolut
progress
brain
edema
date
known
effect
medic
treatment
fh
ifn
therapi
proven
littl
valu
set
enthusiasm
charcoal
hemoperfus
declin
sinc
recent
report
random
control
trial
surviv
prolong
patient
fh
recent
report
infus
result
increas
patient
surviv
patient
fh
tabl
furthermor
three
patient
recurr
hbv
infect
follow
liver
transplant
infus
pge
result
clearanc
hbsag
hbcag
liver
amelior
fh
manuscript
prepar
three
patient
requir
oral
pg
maintain
remiss
although
mechan
amelior
effect
known
pg
may
exert
benefici
effect
decreas
express
class
ii
antigen
inhibit
induct
monocytemacrophag
pca
prevent
reinfect
hepatocyt
manuscript
prepar
orthotop
liver
transplant
becom
therapi
choic
chronic
endstag
liver
diseas
recent
liver
transplant
perform
patient
fh
initi
result
suggest
effect
form
therapi
select
patient
howev
sever
ill
patient
stage
iii
iv
hepat
encephalopathi
surviv
follow
liver
transplant
thu
transplant
patient
fh
consid
consid
earlier
rather
patient
laps
stage
iv
hepat
coma
control
trial
demonstr
efficaci
pg
agent
transplant
remain
treatment
choic
fh
pathogenesi
fh
b
well
understood
howev
bodi
evid
suggest
hbv
directli
cytopath
hepatocyt
rather
diseas
may
mediat
humor
cellular
immun
respons
viral
infect
hepatocyt
time
sever
injuri
usual
absenc
serolog
virolog
marker
hbv
infect
although
signific
number
patient
fh
shown
antihbsag
aggreg
hbsag
antihbsag
demonstr
sinusoid
liver
parenchyma
surviv
hepatocyt
devoid
hepat
viral
antigen
hbvdna
predomin
cytotox
cell
liver
time
sever
injuri
would
argu
favor
cellmedi
immun
respons
clearanc
viru
lesion
fulmin
hepat
failur
occasion
accompani
fibrin
thrombi
deposit
resembl
lesion
dissemin
schwartzman
reaction
observ
suggest
participatori
role
activ
immun
coagul
system
diseas
process
known
monocytemacrophag
endotheli
cell
respons
endotoxin
viral
antigen
immun
complex
produc
proteas
capabl
initi
fibrin
format
could
result
microcirculatori
thrombosi
hepatocyt
hypoxia
progress
necrosi
sequenc
event
clearli
elucid
mhv
infect
vivo
microscop
studi
transillumin
liver
mhvinfect
mice
show
local
round
area
absent
blood
flow
correspond
lesion
seen
cast
studi
decreas
veloc
red
blood
cell
adjac
sinusoid
complet
stasi
blood
flow
observ
area
transmiss
electron
microscop
studi
liver
infect
mice
confirm
obstruct
sinusoid
lumen
protrud
line
cell
platelet
fibrin
studi
demonstr
microvascular
blockag
may
initi
step
lead
necrosi
model
fh
known
eicosinoid
leukotrien
repres
extrem
potent
mediat
inflamm
anaphylact
reaction
pg
appear
primarili
vasodilatori
peptidoleukotrien
mainli
vasoconstrict
treatment
anim
leukotrien
shown
result
fh
thu
suggest
possibl
role
compound
liver
injuri
well
other
observ
benefici
effect
exogen
pg
pge
treatment
fh
experiment
anim
model
fh
man
pg
e
seri
known
inhibit
induct
monocytemacrophag
pca
activ
cytotox
cell
thu
imbal
product
prostanoid
leukotrien
fh
may
account
least
part
evolut
fh
conclus
evid
exist
cellular
humor
immunemedi
process
result
hepat
necrosi
fh
activ
immun
coagul
system
appear
integr
part
inflammatori
process
result
fibrin
thrombi
demonstr
liver
kidney
lung
patient
fh
benefici
role
pg
treatment
fh
demonstr
control
trial
requir
firmli
establish
efficaci
agent
present
liver
transplant
remain
treatment
choic
select
patient
fh
studi
role
immun
system
pathogenesi
diseas
requir
devis
effect
therapeut
strategi
